ATE317699T1 - Glucocorticoid receptor antagonisten zur behandlung von demenz - Google Patents

Glucocorticoid receptor antagonisten zur behandlung von demenz

Info

Publication number
ATE317699T1
ATE317699T1 AT98950912T AT98950912T ATE317699T1 AT E317699 T1 ATE317699 T1 AT E317699T1 AT 98950912 T AT98950912 T AT 98950912T AT 98950912 T AT98950912 T AT 98950912T AT E317699 T1 ATE317699 T1 AT E317699T1
Authority
AT
Austria
Prior art keywords
dementia
glucocorticoid receptor
receptor antagonist
treatment
receptor antagonists
Prior art date
Application number
AT98950912T
Other languages
German (de)
English (en)
Inventor
Alan F Schatzberg
Joseph K Belanoff
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE317699T1 publication Critical patent/ATE317699T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AT98950912T 1998-05-15 1998-10-05 Glucocorticoid receptor antagonisten zur behandlung von demenz ATE317699T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8570398P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
ATE317699T1 true ATE317699T1 (de) 2006-03-15

Family

ID=22193399

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950912T ATE317699T1 (de) 1998-05-15 1998-10-05 Glucocorticoid receptor antagonisten zur behandlung von demenz

Country Status (12)

Country Link
US (1) US6369046B1 (enExample)
EP (1) EP1076562B1 (enExample)
JP (3) JP2003505336A (enExample)
KR (1) KR20010043630A (enExample)
CN (1) CN1130200C (enExample)
AT (1) ATE317699T1 (enExample)
AU (1) AU756818B2 (enExample)
CA (1) CA2328411C (enExample)
DE (1) DE69833502T2 (enExample)
IL (1) IL139672A (enExample)
NZ (1) NZ507449A (enExample)
WO (1) WO1999059596A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
WO2001039664A1 (en) * 1999-12-02 2001-06-07 The General Hospital Corporation Method and apparatus for measuring indices of brain activity
US20010046470A1 (en) * 2000-05-10 2001-11-29 Kieko Morita Diagnoses and treatment of disorders using an alternative glucose pathway
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
IL158744A0 (en) * 2001-05-04 2004-05-12 Corcept Therapeutics Inc Methods for treating delirium using glucocorticoid receptor-specific antagonists
CN1547473A (zh) 2001-07-23 2004-11-17 �Ƹ��� 预防由抗精神病药物引起的体重增加的方法
CN1556708A (zh) * 2001-08-31 2004-12-22 �Ƹ��� 抑制成年唐氏综合症患者认知退化的方法
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
US8476254B2 (en) * 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
US7473903B2 (en) * 2003-02-12 2009-01-06 General Electric Company Method and apparatus for deposited hermetic cover for digital X-ray panel
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
WO2008080083A2 (en) * 2006-12-22 2008-07-03 Washington University High performance imaging system for diffuse optical tomography and associated method of use
US9480425B2 (en) * 2008-04-17 2016-11-01 Washington University Task-less optical mapping of dynamic brain function using resting state functional connectivity
JP2013511732A (ja) * 2009-11-24 2013-04-04 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 神経障害の診断、診断補助および／またはその進行のモニタリングのための方法、キットおよび試薬
PL2576582T3 (pl) * 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
WO2015187988A1 (en) * 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
US10261310B2 (en) 2016-06-27 2019-04-16 Amazon Technologies, Inc. Amorphous silicon layer as optical filter for thin film transistor channel
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
US12194036B2 (en) * 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
ATE363908T1 (de) 1996-04-09 2007-06-15 Univ Edinburgh Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen

Also Published As

Publication number Publication date
CN1292701A (zh) 2001-04-25
CA2328411C (en) 2008-12-16
AU756818B2 (en) 2003-01-23
US6369046B1 (en) 2002-04-09
CA2328411A1 (en) 1999-11-25
EP1076562A1 (en) 2001-02-21
IL139672A (en) 2005-11-20
WO1999059596A1 (en) 1999-11-25
JP2009051864A (ja) 2009-03-12
HK1032535A1 (en) 2001-07-27
EP1076562B1 (en) 2006-02-15
JP2003505336A (ja) 2003-02-12
DE69833502D1 (de) 2006-04-20
JP2009185067A (ja) 2009-08-20
AU9683398A (en) 1999-12-06
DE69833502T2 (de) 2006-09-28
IL139672A0 (en) 2002-02-10
NZ507449A (en) 2003-08-29
CN1130200C (zh) 2003-12-10
KR20010043630A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
ATE317699T1 (de) Glucocorticoid receptor antagonisten zur behandlung von demenz
ATE406166T1 (de) Verfahren zur prävention von gewichtszunahme infolge von antipsychotika
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
EP1156792A4 (en) METHOD AND COMPOSITION FOR TREATING IRRITABLE COLON SYNDROME WITH LOW DOSES OF OPIOID RECEPTOR ANTAGONISTS
NO20003534D0 (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
ATE267595T1 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DE60229411D1 (de) Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
IL164793A0 (en) Methods for increasing the therapeutic response toelectroconvulsive therapy ("ect")
DE69432595D1 (de) Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
ATE317268T1 (de) Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
ATE492281T1 (de) Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium
DE60006948T2 (de) Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
EP1726307A3 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties